Cargando…
Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
BACKGROUND: Cholangiocytes are the target cells of cholangiopathies including primary sclerosing cholangitis (PSC). Vimentin is an intermediate filament protein that has been found in various types of mesenchymal cells. The aim of this study is to evaluate the role of vimentin in the progression of...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838376/ https://www.ncbi.nlm.nih.gov/pubmed/31522982 http://dx.doi.org/10.1016/j.ebiom.2019.09.013 |
_version_ | 1783467210865377280 |
---|---|
author | Zhou, Tianhao Kyritsi, Konstantina Wu, Nan Francis, Heather Yang, Zhihong Chen, Lixian O'Brien, April Kennedy, Lindsey Ceci, Ludovica Meadows, Vik Kusumanchi, Praveen Wu, Chaodong Baiocchi, Leonardo Skill, Nicholas J. Saxena, Romil Sybenga, Amelia Xie, Linglin Liangpunsakul, Suthat Meng, Fanyin Alpini, Gianfranco Glaser, Shannon |
author_facet | Zhou, Tianhao Kyritsi, Konstantina Wu, Nan Francis, Heather Yang, Zhihong Chen, Lixian O'Brien, April Kennedy, Lindsey Ceci, Ludovica Meadows, Vik Kusumanchi, Praveen Wu, Chaodong Baiocchi, Leonardo Skill, Nicholas J. Saxena, Romil Sybenga, Amelia Xie, Linglin Liangpunsakul, Suthat Meng, Fanyin Alpini, Gianfranco Glaser, Shannon |
author_sort | Zhou, Tianhao |
collection | PubMed |
description | BACKGROUND: Cholangiocytes are the target cells of cholangiopathies including primary sclerosing cholangitis (PSC). Vimentin is an intermediate filament protein that has been found in various types of mesenchymal cells. The aim of this study is to evaluate the role of vimentin in the progression of biliary damage/liver fibrosis and whether there is a mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) model of PSC. METHODS: In vivo studies were performed in 12 wk. Mdr2(−/−) male mice with or without vimentin Vivo-Morpholino treatment and their corresponding control groups. Liver specimens from human PSC patients, human intrahepatic biliary epithelial cells (HIBEpiC) and human hepatic stellate cell lines (HHSteCs) were used to measure changes in epithelial-to-mesenchymal transition (EMT). FINDINGS: There was increased mesenchymal phenotype of cholangiocytes in Mdr2(−/−) mice, which was reduced by treatment of vimentin Vivo-Morpholino. Concomitant with reduced vimentin expression, there was decreased liver damage, ductular reaction, biliary senescence, liver fibrosis and TGF-β1 secretion in Mdr2(−/−) mice treated with vimentin Vivo-Morpholino. Human PSC patients and derived cell lines had increased expression of vimentin and other mesenchymal markers compared to healthy controls and HIBEpiC, respectively. In vitro silencing of vimentin in HIBEpiC suppressed TGF-β1-induced EMT and fibrotic reaction. HHSteCs had decreased fibrotic reaction and increased cellular senescence after stimulation with cholangiocyte supernatant with reduced vimentin levels. INTERPRETATION: Our study demonstrated that knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes, which leads to decreased biliary senescence and liver fibrosis. Inhibition of vimentin may be a key therapeutic target in the treatment of cholangiopathies including PSC. FUND: National Institutes of Health (NIH) awards, VA Merit awards. |
format | Online Article Text |
id | pubmed-6838376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-68383762019-11-12 Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC) Zhou, Tianhao Kyritsi, Konstantina Wu, Nan Francis, Heather Yang, Zhihong Chen, Lixian O'Brien, April Kennedy, Lindsey Ceci, Ludovica Meadows, Vik Kusumanchi, Praveen Wu, Chaodong Baiocchi, Leonardo Skill, Nicholas J. Saxena, Romil Sybenga, Amelia Xie, Linglin Liangpunsakul, Suthat Meng, Fanyin Alpini, Gianfranco Glaser, Shannon EBioMedicine Research paper BACKGROUND: Cholangiocytes are the target cells of cholangiopathies including primary sclerosing cholangitis (PSC). Vimentin is an intermediate filament protein that has been found in various types of mesenchymal cells. The aim of this study is to evaluate the role of vimentin in the progression of biliary damage/liver fibrosis and whether there is a mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) model of PSC. METHODS: In vivo studies were performed in 12 wk. Mdr2(−/−) male mice with or without vimentin Vivo-Morpholino treatment and their corresponding control groups. Liver specimens from human PSC patients, human intrahepatic biliary epithelial cells (HIBEpiC) and human hepatic stellate cell lines (HHSteCs) were used to measure changes in epithelial-to-mesenchymal transition (EMT). FINDINGS: There was increased mesenchymal phenotype of cholangiocytes in Mdr2(−/−) mice, which was reduced by treatment of vimentin Vivo-Morpholino. Concomitant with reduced vimentin expression, there was decreased liver damage, ductular reaction, biliary senescence, liver fibrosis and TGF-β1 secretion in Mdr2(−/−) mice treated with vimentin Vivo-Morpholino. Human PSC patients and derived cell lines had increased expression of vimentin and other mesenchymal markers compared to healthy controls and HIBEpiC, respectively. In vitro silencing of vimentin in HIBEpiC suppressed TGF-β1-induced EMT and fibrotic reaction. HHSteCs had decreased fibrotic reaction and increased cellular senescence after stimulation with cholangiocyte supernatant with reduced vimentin levels. INTERPRETATION: Our study demonstrated that knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes, which leads to decreased biliary senescence and liver fibrosis. Inhibition of vimentin may be a key therapeutic target in the treatment of cholangiopathies including PSC. FUND: National Institutes of Health (NIH) awards, VA Merit awards. Elsevier 2019-09-12 /pmc/articles/PMC6838376/ /pubmed/31522982 http://dx.doi.org/10.1016/j.ebiom.2019.09.013 Text en Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research paper Zhou, Tianhao Kyritsi, Konstantina Wu, Nan Francis, Heather Yang, Zhihong Chen, Lixian O'Brien, April Kennedy, Lindsey Ceci, Ludovica Meadows, Vik Kusumanchi, Praveen Wu, Chaodong Baiocchi, Leonardo Skill, Nicholas J. Saxena, Romil Sybenga, Amelia Xie, Linglin Liangpunsakul, Suthat Meng, Fanyin Alpini, Gianfranco Glaser, Shannon Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC) |
title | Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC) |
title_full | Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC) |
title_fullStr | Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC) |
title_full_unstemmed | Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC) |
title_short | Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC) |
title_sort | knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the mdr2(−/−) mouse model of primary sclerosing cholangitis (psc) |
topic | Research paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838376/ https://www.ncbi.nlm.nih.gov/pubmed/31522982 http://dx.doi.org/10.1016/j.ebiom.2019.09.013 |
work_keys_str_mv | AT zhoutianhao knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT kyritsikonstantina knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT wunan knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT francisheather knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT yangzhihong knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT chenlixian knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT obrienapril knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT kennedylindsey knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT ceciludovica knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT meadowsvik knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT kusumanchipraveen knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT wuchaodong knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT baiocchileonardo knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT skillnicholasj knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT saxenaromil knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT sybengaamelia knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT xielinglin knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT liangpunsakulsuthat knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT mengfanyin knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT alpinigianfranco knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc AT glasershannon knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc |